Deping Han is the founder of Biosyngen. Biosyngen has raised $86M in total funding. Latest round: Venture - Series Unknown. Based in Singapore, Singapore.
Deping Han is the CEO and Chief Medical Officer of Biosyngen, a Singapore-based company specializing in cell therapy. The company focuses on developing cutting-edge immunotherapies, particularly for solid tumors, leveraging technologies like CAR-T and TCR-T. Biosyngen has established a partnership with Science City (Guangzhou) Investment Group Co., Ltd. (SCI Group) to build a biomedical base in China, with an estimated investment of 500 million yuan.
Full founder directory · Investor directory · Company funding database · Fundraising library